Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer

Steven E. Schild, James A. Bonner, Thomas G. Shanahan, Burke J. Brooks, Randolph S. Marks, Susan M. Geyer, Shauna L. Hillman, Gist H. Farr, Henry D. Tazelaar, James E. Krook, Francois J. Geoffroy, Muhammad Salim, Robert M. Arusell, James A. Mailliard, Paul L. Schaefer, James R. Jett

Research output: Contribution to journalArticle

132 Scopus citations

Abstract

Purpose This Phase III study was performed to determine whether twice-daily (b.i.d.) radiotherapy (RT) resulted in better survival than once-daily (q.d.) RT for patients with limited-stage small-cell lung cancer (LD-SCLC). Methods and materials A total of 310 patients with LD-SCLC initially received three cycles of etoposide and cisplatin. Subsequently, the 261 patients without significant progression were randomized to two cycles of etoposide and cisplatin plus either q.d. RT (50.4 Gy in 28 fractions) or split-course b.i.d. RT (24 Gy in 16 fractions, a 2.5-week break, and 24 Gy in 16 fractions) to the chest. Patients then received a sixth cycle of etoposide and cisplatin followed by prophylactic cranial RT. Results Follow-up ranged from 4.6 to 11.9 years (median, 7.4 years). The median survival and 5-year survival rate from randomization was 20.6 months and 21% for patients who received q.d. RT compared with 20.6 months and 22% for those who received b.i.d. RT (p = 0.68), respectively. No statistically significant differences were found in the rates of progression (p = 0.68), intrathoracic failure (p = 0.45), in-field failure (p = 0.62), or distant failure (p = 0.82) between the two treatment arms. No statistically significant difference was found in the overall rate of Grade 3 or worse (p = 0.83) or Grade 4 or worse toxicity (p = 0.95). Grade 3 or worse esophagitis (p = 0.05) was more common in the b.i.d. arm. Grade 5 toxicity occurred in 4 (3%) of 130 patients who received b.i.d. RT compared with 0 (0%) of 131 who received q.d. RT (p = 0.04). Conclusion Although this study did not demonstrate an advantage to split-course b.i.d. RT, the long-term survival was favorable, likely reflecting the positive influences of concurrent combined modality therapy and prophylactic cranial RT.

Original languageEnglish (US)
Pages (from-to)943-951
Number of pages9
JournalInternational Journal of Radiation Oncology Biology Physics
Volume59
Issue number4
DOIs
StatePublished - Jul 15 2004

Keywords

  • Dose fractionation
  • Limited stage
  • Radiotherapy
  • Randomized prospective study
  • Small-cell lung cancer

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Schild, S. E., Bonner, J. A., Shanahan, T. G., Brooks, B. J., Marks, R. S., Geyer, S. M., Hillman, S. L., Farr, G. H., Tazelaar, H. D., Krook, J. E., Geoffroy, F. J., Salim, M., Arusell, R. M., Mailliard, J. A., Schaefer, P. L., & Jett, J. R. (2004). Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 59(4), 943-951. https://doi.org/10.1016/j.ijrobp.2004.01.055